an31647098-8k.htm
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
__________

FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
 

Date of Report (Date of earliest event reported):  October 28, 2014

 
AngioDynamics, Inc.
(Exact Name of Registrant as Specified in Charter)


Delaware
000-50761
11-3146460
     
(State or Other Jurisdiction of Incorporation)
(Commission File
Number)
(IRS Employer
Identification No.)

 
14 Plaza Drive, Latham, New York      12110
 
(Address of Principal Executive Offices)                 (Zip Code)
 
 
(518) 798-1215
 
(Registrant’s telephone number, including area code)
 
 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
 
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
 
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
 
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b))
 
 
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4 (c))
 

 
 
 

Item 5.07 – Submission of Matters to a Vote of Security Holders.

(a)  
AngioDynamics’ Annual Meeting of Shareholders was held on October 28, 2014.

(b)  
Shareholders voted on the matters set forth below.

1.  
The nominees for election to the Board of Directors were elected, each as a Class II director to serve until the 2017 Annual Meeting of Shareholders, based upon the following votes:

Nominee
Votes For
Withheld
Broker Non Votes
  
         
Joseph M. DeVivo
30,784,361
354,155
2,969,502
  
         
Howard W. Donnelly
30,778,521
359,995
2,969,502
  
         
Sriram Venkataraman
27,744,110
3,394,406
2,969,502
  
 
 
2.  
The proposal to ratify the appointment of PricewaterhouseCoopers LLP as AngioDynamics’ independent registered public accounting firm for the fiscal year ending May 31, 2015 was approved based upon the following votes:

Votes for approval
33,703,988
  
Votes against
386,939
  
Abstentions
17,091
  
There were no broker non-votes for this item.


3.  
The proposal to approve, on an advisory basis, AngioDynamics’ executive compensation for its named executive officers was approved based upon the following votes:

Votes for approval
29,789,194
  
Votes against
1,051,132
  
Abstentions
298,190
  
Broker non votes
2,969,502
  


4.  
The proposal to approve an amendment to the AngioDynamics, Inc. 2004 Stock and Incentive Award Plan was approved based upon the following votes:

Votes for approval
28,710,153
  
Votes against
2,411,637
  
Abstentions
16,726
  
Broker non votes
2,969,502
  


 
 
 

5.  
The proposal to approve an amendment to the AngioDynamics, Inc. Employee Stock Purchase Plan was approved based upon the following votes:

Votes for approval
30,922,290
  
Votes against
206,064
  
Abstentions
10,162
  
Broker non votes
2,969,502
  


6.  
The proposal to approve an amendment to the AngioDynamics, Inc. Amended and Restated Certificate of Incorporation was approved based upon the following votes:

Votes for approval
31,043,767
  
Votes against
2,974,950
  
Abstentions
89,301
  
Broker non votes
2,969,502
  


(c)  
Not applicable.

(d)  
Not applicable.




 
 
 


SIGNATURE
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

  ANGIODYNAMICS, INC.  
  (Registrant)  
     
       
Date: October 31, 2014
By:
/s/ Stephen A. Trowbridge  
    Stephen A. Trowbridge  
    Senior Vice President and  
    General Counsel